Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Regeneron (REGN – Research Report) and Surgery ...

Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron ...

Oppenheimer keeps an Outperform rating on Regeneron (REGN) with a $925 price target after the FDA denied the company’s attempt to extend the ...

If an investor was to purchase shares of REGN stock at the current price level of $616.05/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

FDA accepts Regeneron's sBLA for Eylea HD in RVO with priority review; QUASAR data supports monthly dosing, target action date set for August 2025.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report ... rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 62. ...

Evergreen Capital Management boosted its Regeneron stake by 362.9%, snatching up 3,030 more shares and flexing some serious ...

The average 12 month price objective among analysts that have covered the stock in the last year is $966.88. Several research firms recently commented on REGN. BMO Capital Markets decreased their ...